CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Neurology

• Publication date

  2003-02-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/01.WNL.0000046581.81650.D0PMID 12601108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain

  2004cited by this paper
• Cerebral amyloid angiopathy and cognitive function: The HAAS autopsy study

  2002cited by this paper
• Cholesterol and neuropathologic markers of AD: a population-based autopsy study.

  2002cited by this paper
• Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study.

  2002cited by this paper
• Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease

  2002cited by this paper
• Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.

  2001cited by this paper
• Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

  2001cited by this paper
• Metabolic regulation of brain Abeta by neprilysin.

  2001cited by this paper
• Cerebrospinal fluid beta-amyloid and tau proteins for the diagnosis of Alzheimer disease.

  2001cited by this paper
• Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

  2001cited by this paper
• How well does the CSF inform upon pathology in the brain in Creutzfeldt–Jakob and Alzheimer's diseases?

  2001cited by this paper
• Metabolic Regulation of Brain Aβ by Neprilysin

  2001cited by this paper
• Cerebral Amyloid Angiopathy: Accumulation of Aβ in Interstitial Fluid Drainage Pathways in Alzheimer's Disease

  2000cited by this paper
• CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

  2000cited by this paper
• Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma

  2000cited by this paper
• The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide

  1999cited by this paper
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

  1998cited by this paper
• Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease.

  1998cited by this paper
• Microscope field size and the neuropathologic criteria for Alzheimer's disease

  1997cited by this paper
• Review: David Oppenheimer Memorial Lecture 1995: Some neuropathological aspects of Alzheimer's disease and its relevance to other disciplines *

  1996cited by this paper
• David Oppenheimer Memorial Lecture 1995

  1996cited by this paper
• Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study.

  1996cited by this paper
• Brain Parenchymal and Microvascular Amyloid in Alzheimer's Disease

  1996cited by this paper
• Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Kunitz Protease Inhibitor‐Containing Amyloid β Protein Precursor Immunoreactivity in Alzheimer's Disease

  1992cited by this paper
• Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view.

  1992cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

  1990cited by this paper

• Biofluid biomarkers in Alzheimer’s disease and other neurodegenerative dementias

  2026cites this paper
• Long-term effects of forty-hertz auditory stimulation as a treatment of Alzheimer’s disease: Insights from an aged monkey model study

  2026cites this paper
• Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO

  2025cites this paper
• Computational Risk Stratification of Preclinical Alzheimer’s in Younger Adults

  2025cites this paper
• Cerebrospinal Fluid Beta‐Amyloid Concentration and Clinical and Radiographic Manifestations of Cerebral Amyloid Angiopathy

  2025cites this paper
• Association of Brain and Ventricular Boundary Shift Integral Measurements with CSF Biomarkers: A Case-Control Study.

  2025cites this paper
• Dementia Prevention, It’s Background and Technologies

  2025cites this paper
• Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice

  2025cites this paper
• Blood biomarkers for clinical applications in Alzheimer's disease: A narrative review

  2025cites this paper
• Low synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease.

  2025cites this paper
• Biomarker-related phospho-tau217 appears in synapses around Aβ plaques prior to tau tangle in cerebral cortex of preclinical Alzheimer's disease.

  2025cites this paper
• A multivariable cis-Mendelian randomization method robust to weak instrument bias and horizontal pleiotropy bias

  2025cites this paper
• Mechanisms of Dural Involvement in Cerebral Amyloid Angiopathy

  2025cites this paper
• Inflammation biomarkers and Alzheimer's disease: A pilot study using NULISAseq

  2025cites this paper
• From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach

  2024cites this paper
• Biofluid biomarkers for Alzheimer’s disease

  2024cites this paper
• Alzheimer’s disease biomarkers and their current use in clinical research and practice

  2024cites this paper
• Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer’s disease and other neurodegenerative diseases

  2024cites this paper
• Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer’s Disease

  2024cites this paper
• Alzheimer's disease cerebrospinal fluid biomarkers and kidney function in normal and cognitively impaired older adults

  2024cites this paper
• Higher Cerebrospinal Fluid Levels of Amyloid-β40 Following Traumatic Brain Injury Relate to Confrontation Naming Performance

  2024cites this paper
• Strategies for measuring concentrations and forms of amyloid-β peptides.

  2024cites this paper
• Chemically Self-Assembled Monolayer Semiconducting Single-Walled Carbon Nanotube-Based Biosensor Platform for Amyloid-β Detection.

  2024cites this paper
• Regulation of Glycolysis-Derived L-lactate Production in Astrocytes Rescues the Memory Deficits and Aβ Burden in Early Alzheimer's Disease Models.

  2024cites this paper
• Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease

  2024cites this paper
• Analysis of Alzheimer's Disease-Related Mortality Rates Among the Elderly Populations Across the United States: An Analysis of Demographic and Regional Disparities from 1999 to 2020.

  2024cites this paper
• Where Should I Draw the Line: PET-Driven, Data-Driven, or Manufacturer Cut-Off?

  2024cites this paper
• Connecting genomic and proteomic signatures of amyloid burden in the brain

  2024cites this paper
• CSF β-Amyloid and Tau Biomarker Changes in Veterans With Mild Traumatic Brain Injury.

  2024cites this paper
• Translating NIA‐AA criteria into usual practice: Report from the ReDeMa Project

  2024cites this paper
• Association of cigarette smoking with cerebrospinal fluid biomarkers of insulin sensitivity and neurodegeneration

  2024cites this paper
• Traumatic Brain Injury and Genetic Risk for Alzheimer’s Disease Impact Cerebrospinal Fluid β-Amyloid Levels in Vietnam War Veterans

  2024cites this paper
• Paradoxical attenuation of early amyloid-induced cognitive impairment and synaptic plasticity in an aged APP/Tau bigenic rat model

  2024cites this paper
• Elevated cerebrospinal fluid biomarkers of neuroinflammation and neuronal damage in essential hypertension with secondary insomnia: Implications for Alzheimer's disease risk.

  2024cites this paper
• The Effects of PICALM rs3851179 and Age on Brain Atrophy and Cognition Along the Alzheimer’s Disease Continuum

  2024cites this paper
• Relationship Between Cerebrospinal Fluid Alzheimer’s Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review

  2024cites this paper
• Differential involvement of hippocampal subfields in the relationship between Alzheimer's pathology and memory interference in older adults

  2023cites this paper
• Biomarkers of Alzheimer’s Disease: Past, Present and Future Clinical Use

  2023cites this paper
• Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

  2023cites this paper
• Fluid biomarkers in Alzheimer's disease.

  2023cites this paper
• Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia

  2023cites this paper
• Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice

  2023cites this paper
• Progression of cerebral amyloid angiopathy: a pathophysiological framework.

  2023cites this paper
• Recent advances in electrochemical biosensors for the detection of Aβ42, a biomarker for Alzheimer disease diagnosis

  2023cites this paper
• CSF Aβ40 Levels Do Not Correlate with the Clinical Manifestations of Alzheimer’s Disease

  2023cites this paper
• Small-molecule theranostics in Alzheimer's disease.

  2023cites this paper
• Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.

  2023cites this paper
• Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer’s Disease: An Overview of Tests for Clinical Practice in the United States and Europe

  2023cites this paper
• Distinct CSF biomarker-associated DNA methylation in Alzheimer’s disease and cognitively normal subjects

  2023cites this paper
• Early Alzheimer’s disease pathology in human cortex is associated with a transient phase of distinct cell states

  2023cites this paper
• The Role of CSF Transthyretin in Human Alzheimer's Disease: Offense, Defense, or not so Innocent Bystander.

  2023cites this paper
• Associations between Alzheimer's disease biomarkers and postoperative delirium or cognitive dysfunction

  2023cites this paper
• Distinct CSF biomarker-associated DNA methylation in Alzheimer’s disease and cognitively normal subjects

  2023cites this paper
• Lower Cerebrospinal Fluid Amyloid-β42 Predicts Sooner Time to Antipsychotic Use in Alzheimer’s Disease

  2023cites this paper
• CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

  2023cites this paper
• Early Alzheimer's disease pathology in human cortex involves transient cell states.

  2023cites this paper
• Longitudinal changes in metabolic network activity in early Alzheimer's disease

  2023cites this paper
• Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

  2023cites this paper
• Application of peptide biomarkers in life analysis based on liquid chromatography–mass spectrometry technology

  2022cites this paper
• Identification and validation of Alzheimer’s disease-related metabolic brain pattern in biomarker confirmed Alzheimer’s dementia patients

  2022cites this paper
• Apolipoprotein E Genotype e2: Neuroprotection and Its Limits

  2022cites this paper
• Clinical utility of fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis

  2022cites this paper
• Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention

  2022cites this paper
• Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.

  2022cites this paper
• The Relationship Between Suboptimal Social Networks and Postoperative Delirium: The PNDABLE Study

  2022cites this paper
• Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

  2022cites this paper
• The Influence of Orthopedic Surgery on Circulating Metabolite Levels, and their Associations with the Incidence of Postoperative Delirium

  2022cites this paper
• Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts

  2022cites this paper
• Biofluid‐based biomarkers for Alzheimer's disease–related pathologies: An update and synthesis of the literature

  2022cites this paper
• Language patterns in Japanese patients with Alzheimer disease: A machine learning approach

  2022cites this paper
• Salivary Aβ_1–42 may be a quick-tested biomarker for clinical use in Alzheimer’s disease: a meta-analysis

  2022cites this paper
• Direct coupling of fiber-in-tube solid-phase microextraction with tandem mass spectrometry to determine amyloid beta peptides as biomarkers for Alzheimer's disease in cerebrospinal fluid samples.

  2022cites this paper
• PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid β42, and Phosphorylated Tau in the Elderly

  2022cites this paper
• Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer’s disease：a systematic review with meta-analysis

  2022cites this paper
• Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends

  2022cites this paper
• Neuropathology‐based APOE genetic risk score better quantifies Alzheimer's risk

  2022cites this paper
• PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

  2022cites this paper
• Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers.

  2022cites this paper
• CSF biomarkers in patients with epilepsy in Alzheimer’s disease: a nation-wide study

  2022cites this paper
• Is liquid biopsy mature enough for the diagnosis of Alzheimer’s disease?

  2022cites this paper
• Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

  2022cites this paper
• Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis

  2022cites this paper
• Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks

  2022cites this paper
• Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

  2021cites this paper
• The effect of electroconvulsive therapy on neuroinflammation, behavior and amyloid plaques in the 5xFAD mouse model of Alzheimer’s disease

  2021cites this paper
• Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays

  2021cites this paper
• Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia

  2021cites this paper
• Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease.

  2021cites this paper
• The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

  2021cites this paper
• Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age.

  2021cites this paper
• The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau

  2021cites this paper
• Blood‐based biomarkers for Alzheimer's disease

  2021cites this paper
• Biomarkers used in Alzheimer's Disease diagnosis, treatment, and prevention.

  2021cites this paper
• Development of a Low-Molecular-Weight Aβ42 Detection System Using a Enzyme-Linked Peptide Assay

  2021cites this paper
• Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment

  2021cites this paper
• Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?

  2021cites this paper
• Diagnostic biomarkers in Alzheimer’s disease

  2021cites this paper
• Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy

  2021cites this paper
• Different Sides of Depression in the Elderly: An In-depth View on the Role of Aβ Peptides.

  2021cites this paper
• Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?

  2021cites this paper